Published • loading... • Updated
Grail Rallies as FDA Staff Flags No Major Concerns for Multi-Cancer Test
The panel will weigh mixed trial results, including 14% fewer stage IV diagnoses and no proven reduction in cancer deaths.
- On Monday, GRAIL shares surged 35% after FDA staff reviewers raised no major concerns about the accuracy of the Galleri blood test designed to detect more than 50 cancers, ahead of Wednesday's advisory panel vote on premarket approval.
- Currently sold by prescription without FDA approval, Galleri is designed to detect more than 50 cancers and complements rather than replaces standard screenings like mammograms or colonoscopies, according to GRAIL.
- Data from the NHS-Galleri trial indicates a 52% positive predictive value, meaning roughly half of positive results are ultimately confirmed as cancer, though the trial missed its primary goal of significantly reducing late-stage diagnoses.
- While the advisory panel's Wednesday vote provides advice rather than a final decision, FDA approval would facilitate insurance coverage; Congress voted to allow Medicare reimbursement for such tests starting in 2028 after full agency review.
- Piper Sandler analyst David Westenberg called the FDA's document release "constructive for Grail," though the agency asked advisers to discuss whether current evidence supports Galleri's characterization as an "early detection" test.
Insights by Ground AI
11 Articles
11 Articles
Grail rallies as FDA staff flags no major concerns for multi-cancer test
By Christy Santhosh and Padmanabhan Ananthan Sept 21 (Reuters) - The US FDA's staff reviewers did not raise major concerns about the accuracy and safety of Grail's blood test designed to detect more than 50 cancers, sending the company's shares soari...
Coverage Details
Total News Sources11
Leaning Left0Leaning Right2Center4Last UpdatedBias Distribution67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
C 67%
R 33%
Factuality
To view factuality data please Upgrade to Premium
